Fusobacterium nucleatum-induced imbalance in microbiome-derived butyric acid levels promotes the occurrence and development of colorectal cancer

World J Gastroenterol. 2024 Apr 14;30(14):2018-2037. doi: 10.3748/wjg.v30.i14.2018.

Abstract

Background: Colorectal cancer (CRC) ranks among the most prevalent malignant tumors globally. Recent reports suggest that Fusobacterium nucleatum (F. nucleatum) contributes to the initiation, progression, and prognosis of CRC. Butyrate, a short-chain fatty acid derived from the bacterial fermentation of soluble dietary fiber, is known to inhibit various cancers. This study is designed to explore whether F. nucleatum influences the onset and progression of CRC by impacting the intestinal metabolite butyric acid.

Aim: To investigate the mechanism by which F. nucleatum affects CRC occurrence and development.

Methods: Alterations in the gut microbiota of BALB/c mice were observed following the oral administration of F. nucleatum. Additionally, DLD-1 and HCT116 cell lines were exposed to sodium butyrate (NaB) and F. nucleatum in vitro to examine the effects on proliferative proteins and mitochondrial function.

Results: Our research indicates that the prevalence of F. nucleatum in fecal samples from CRC patients is significantly greater than in healthy counterparts, while the prevalence of butyrate-producing bacteria is notably lower. In mice colonized with F. nucleatum, the population of butyrate-producing bacteria decreased, resulting in altered levels of butyric acid, a key intestinal metabolite of butyrate. Exposure to NaB can impair mitochondrial morphology and diminish mitochondrial membrane potential in DLD-1 and HCT116 CRC cells. Consequently, this leads to modulated production of adenosine triphosphate and reactive oxygen species, thereby inhibiting cancer cell proliferation. Additionally, NaB triggers the adenosine monophosphate-activated protein kinase (AMPK) signaling pathway, blocks the cell cycle in HCT116 and DLD-1 cells, and curtails the proliferation of CRC cells. The combined presence of F. nucleatum and NaB attenuated the effects of the latter. By employing small interfering RNA to suppress AMPK, it was demonstrated that AMPK is essential for NaB's inhibition of CRC cell proliferation.

Conclusion: F. nucleatum can promote cancer progression through its inhibitory effect on butyric acid, via the AMPK signaling pathway.

Keywords: Adenosine monophosphate-activated protein kinase signal pathway; Butyric acid; Colorectal cancer; Fusobacterium nucleatum; Gut microbiota.

MeSH terms

  • Animals
  • Butyric Acid* / metabolism
  • Butyric Acid* / pharmacology
  • Cell Line, Tumor
  • Cell Proliferation* / drug effects
  • Colorectal Neoplasms* / metabolism
  • Colorectal Neoplasms* / microbiology
  • Colorectal Neoplasms* / pathology
  • Disease Models, Animal
  • Disease Progression
  • Dysbiosis
  • Feces* / microbiology
  • Female
  • Fusobacterium Infections / microbiology
  • Fusobacterium nucleatum*
  • Gastrointestinal Microbiome* / drug effects
  • HCT116 Cells
  • Humans
  • Male
  • Membrane Potential, Mitochondrial / drug effects
  • Mice
  • Mice, Inbred BALB C*
  • Mitochondria / drug effects
  • Mitochondria / metabolism

Substances

  • Butyric Acid